Saint Petersburg, FL - (NewMediaWire) - April 23, 2019 - Apotheca Biosciences (OTC PINK: CBDC), a developer of cutting-edge medical & pharmaceutical products, nutraceuticals, and cannabis delivery technologies for the health care and consumer care industry, is pleased to announce incorporation of its newly created subsidiary ProMED Biosciences, Inc. ProMED Biosciences will ship their newest flag-ship pharma grade CBD product line under the trademarked brand name ProMED. ProMED Biosciences will be carrying cannabidiol (CBD) related products, from tinctures to cosmetics, which are distributed nationally in wellbeing centers, dispensaries, spas, health food stores, vitamin shops, health care providers, online and through distributors. The Company expects substantial revenue potential from ProMED subsidiary.
For CBD infused drinks, the Company is joining forces with CB Scientific (OTC PINK: CBSC) to develop and unveil next generation CBD based energy drinks, chill drinks, water and cold brew coffee for consumers and patients under the brands "Cannavive" and “DAVA”. Hemp based CBD infused drinks will be sold globally through all channels, which may include eBay and Amazon under the brands "Cannavive" and “DAVA”.
For immediate wholesale distribution & pricing please contact firstname.lastname@example.org.
ProMED will initially carry 12 product SKUs which includes:
- 500 mg 30 ml CBD Oil Drops (Isolate)
- 500 mg 30 ml CBD Oil Drops (Full Spectrum)
- 1000 mg 30 ml CBD Tincture (Isolate)
- 1000 mg 30 ml CBD Tincture (Full Spectrum)
- Full Spectrum Vape Juices in 1000 & 1500 mg
- 250 mg 3.4oz Air Pump Pain Cream (Isolate)
- 250 mg 3.4oz Air Pump Pain Cream (Full Spectrum)
- 25 mg Soft Gel Capsule 30 count bottle (Isolate)
- 25 mg Soft Gel Capsule 30 count bottle (Full Spectrum)
- 25 mg Dry Cap Sleep Aid 30 count bottle (Isolate)
- 500 mg OTC Sport Pain Cream (Isolate)
- 320 mg OTC Sport Pain Balm Stick (Isolate)
Full Traceability and Transparency
Our products are carefully developed and formulated from proprietary strains of hemp that have been derived from fully traceable USDA registered industrial hemp farms with full ISO and GMP-compliant traceability reports and COAs. Products have been and may be formulated and manufactured in an FDA registered, ISO 9001-22716, cGMP and OTC certified facilities.
Second Quarter product SKUs will include:
- Hemp Cigarettes
- Cosmetic Line (Limited line)
- Broad Spectrum THC Free Pain Creams in 1000 mg
- Full & Broad-Spectrum Gel Caps & Sleep Capsules in 1000 - 3000 mg
- Broad Spectrum THC Free Tinctures & Oil Drops in 1000 - 3000 mg
- Water Soluble Powders & Liquids
- Pure CBD Crystalline Isolate Nano Water Soluble Liquid Concentrates
The success behind ProMED is the strategic partnerships that have been formed by Apotheca Biosciences, its parent company with companies such as CB Scientific (OTC PINK: CBSC). Apotheca Biosciences has been on the cutting edge of formulations, dedicated to the very best products and formulations that give the consumer of our product piece of mind that they are getting the very best CBD products on today’s market.
Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. The health of our customers takes precedence and our solid business strategy ensures focus on customer well-being. Our goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects our strategy and research. For more information on Apotheca Biosciences, please visit www.apothecabiosciences.com
About ProMED Biosciences Inc. – Science Based Wellbeing
ProMED Biosciences is a developer and manufacturer of medical grade CBD and cannabinoids products that enhances wellbeing and quality of life. ProMED will be distributed nationally in wellbeing centers, dispensaries, spas, health food stores, vitamin shops, health care provider’s offices, online and through distributors.
To request further information about ProMED, please email email@example.com, or visit us on FB @promedcbd and Twitter @promedbio
About Apotheca Biosciences Inc.
Apotheca Biosciences, a biopharmaceutical company, through its divisions, engages in 1) the discovery, development, and commercialization of therapies for the treatment of opioid addiction, sleep disorder, PTSD. Alzheimer's and inflammatory diseases worldwide, 2) develops and manufactures medical devices for precise dosing, and 3) direct to business and consumer CBD enhanced supplements, formulations and cosmetics. The pipeline of products includes, transdermal, sublingual, digestive technologies and medical devices for precise and controlled dosing of cannabinoids. Products such as CannaDERME, a transdermal technology using nano-emulsion for fast absorption of cannabinoid compounds for the general pain market.
To request further information about Apotheca, please email firstname.lastname@example.org, or visit its website at http://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Media Contact: (727) 228-3994
Twitter - @apotheca
Facebook – apotheca